Roivant's Revenue Plummets 65% Amidst Deepening Losses

TL;DR

**Roivant's cash is burning fast, and revenue is collapsing – this stock is a high-risk bet on future pipeline success, or bust.**

AI Summary

Roivant Sciences Ltd. reported a significant decrease in revenue for the three months ended September 30, 2025, falling to $1.571 million from $4.475 million in the prior year, a 64.9% decline. For the six months ended September 30, 2025, revenue decreased to $3.741 million from $12.465 million in 2024, a 70% drop. The company experienced a substantial net loss, with an accumulated deficit of $429.107 million as of September 30, 2025, a stark contrast to the retained earnings of $116.060 million as of March 31, 2025. Cash and cash equivalents plummeted from $2.715 billion on March 31, 2025, to $1.237 billion by September 30, 2025, representing a 54.5% reduction. Marketable securities, however, increased from $2.171 billion to $3.148 billion over the same period. Key business changes include continued significant investment in research and development, which is typical for a biopharmaceutical company, and a reliance on third parties for clinical trials and manufacturing. Risks highlighted include the limited operating history, uncertainties in product development, and the potential for significant operating losses for the foreseeable future. The strategic outlook remains focused on acquiring and in-licensing new product candidates, despite the substantial cash burn.

Why It Matters

Roivant's substantial cash burn and declining revenue signal increased financial pressure, impacting its ability to fund crucial R&D and potentially delaying product candidate development. For investors, this raises concerns about future dilution and the long-term viability of its 'Vant' model. Employees may face uncertainty if cost-cutting measures become necessary, while customers and the broader market could see delays in innovative drug candidates reaching the market. The competitive landscape in biopharmaceuticals demands significant capital, and Roivant's current trajectory could weaken its position against better-capitalized rivals.

Risk Assessment

Risk Level: high — Roivant's cash and cash equivalents decreased by 54.5% from $2.715 billion to $1.237 billion in just six months, indicating a rapid cash burn. The company also reported an accumulated deficit of $429.107 million as of September 30, 2025, compared to retained earnings of $116.060 million on March 31, 2025, demonstrating significant operating losses. The filing explicitly states, "We will likely incur significant operating losses for the foreseeable future and may never achieve sustained profitability."

Analyst Insight

Investors should exercise extreme caution and consider reducing exposure to ROIV given the rapid cash burn and significant revenue decline. Await clearer signs of pipeline success and a path to profitability before considering new positions, as further dilution or capital raises are likely.

Financial Highlights

debt To Equity

N/A

revenue

$1.571M

operating Margin

N/A

total Assets

$5.063B

total Debt

$0.257B

net Income

N/A

eps

N/A

gross Margin

N/A

cash Position

$1.237B

revenue Growth

-64.9%

Revenue Breakdown

Key Numbers

• $1.571M — Revenue for Q3 2025 (Decreased from $4.475M in Q3 2024, a 64.9% decline)
• $3.741M — Revenue for H1 2025 (Decreased from $12.465M in H1 2024, a 70% decline)
• $429.107M — Accumulated Deficit (As of September 30, 2025, compared to $116.060M retained earnings on March 31, 2025)
• $1.237B — Cash and Cash Equivalents (As of September 30, 2025, down from $2.715B on March 31, 2025 (54.5% decrease))
• $3.148B — Marketable Securities (As of September 30, 2025, up from $2.171B on March 31, 2025)
• 695,491,615 — Common Shares Outstanding (As of November 3, 2025)

Key Players & Entities

• Roivant Sciences Ltd. (company) — Registrant for 10-Q filing
• Immunovant, Inc. (company) — Subsidiary mentioned in investor relations
• HanAll Agreement (agreement) — Provides rights to core intellectual property for Immunovant
• FDA (regulator) — U.S. Food and Drug Administration, involved in drug approval
• USPTO (regulator) — U.S. Patent and Trademark Office
• SEC (regulator) — Securities and Exchange Commission
• Nasdaq Global Select Market (market) — Exchange where ROIV common shares are registered
• IMVT-1402 (product_candidate) — Product candidate developed by Immunovant
• batoclimab (product_candidate) — Product candidate developed by Immunovant
• X (social_media_platform) — Social media platform used for company announcements

FAQ

Risk Factors

• Accumulated Deficit and Net Losses [high — financial]: The company has an accumulated deficit of $429.107 million as of September 30, 2025, a significant shift from retained earnings of $116.060 million as of March 31, 2025. This indicates substantial operating losses and a negative equity position, raising concerns about long-term financial sustainability.
• Significant Cash Burn [high — financial]: Cash and cash equivalents decreased by 54.5% from $2.715 billion to $1.237 billion in the six months ended September 30, 2025. This rapid depletion of cash reserves, despite a substantial marketable securities portfolio, highlights the high operational burn rate and potential future funding needs.
• Reliance on Third Parties [medium — operational]: Roivant Sciences relies on third parties for critical functions such as clinical trials and manufacturing. This dependence introduces risks related to quality control, supply chain disruptions, and potential breaches of contract, which could impact product development timelines and costs.
• Limited Operating History [medium — operational]: The company has a limited operating history, which makes it difficult to assess its long-term performance and predict future results. This uncertainty is compounded by the inherent risks in drug development and commercialization.
• Uncertainty in Product Development [high — financial]: The success of Roivant's business model is heavily dependent on the successful development and commercialization of its product candidates. Clinical trial failures, regulatory hurdles, or market acceptance issues could lead to significant financial losses.
• Foreseeable Future Operating Losses [high — financial]: The company anticipates significant operating losses for the foreseeable future due to substantial investments in research and development. This outlook suggests continued cash burn and potential dilution for shareholders if additional financing is required.

Industry Context

Roivant Sciences operates in the highly competitive biopharmaceutical industry, characterized by long development cycles, substantial R&D investment, and significant regulatory oversight. The industry trend involves a focus on acquiring and in-licensing novel drug candidates to build a pipeline, a strategy Roivant actively pursues. Success hinges on navigating complex clinical trials, securing regulatory approvals, and achieving market adoption against established players and emerging biotech firms.

Regulatory Implications

As a biopharmaceutical company, Roivant Sciences is subject to stringent regulations from bodies like the FDA. Delays in clinical trials, failure to meet efficacy or safety standards, or issues with manufacturing processes can lead to significant setbacks and financial losses. Compliance with evolving regulatory landscapes is critical for product approval and market access.

What Investors Should Do

1. Monitor R&D Pipeline Progress
2. Assess Cash Burn Rate and Funding Strategy
3. Evaluate Revenue Generation and Commercialization Efforts

Key Dates

• 2025-09-30: End of Second Fiscal Quarter — Reporting period for the condensed consolidated financial statements, showing a significant decrease in revenue and an increase in accumulated deficit.
• 2025-03-31: End of Fiscal Year — Prior period balance sheet data, showing retained earnings and a higher cash and cash equivalents balance compared to September 30, 2025.

Glossary

Accumulated Deficit

The cumulative net losses of a company since its inception, minus any cumulative net income. It represents a negative balance in retained earnings. (Indicates the company has incurred more losses than profits over its operating history, as evidenced by the $429.107 million deficit as of September 30, 2025.)

Marketable Securities

Investments in financial instruments that are readily tradable on public exchanges and can be quickly converted to cash. (Roivant Sciences holds a significant amount ($3.148 billion as of September 30, 2025), which provides liquidity alongside cash and cash equivalents, though the cash position has significantly decreased.)

Share-based Compensation Expense

The cost recognized for equity awards granted to employees and directors, such as stock options or restricted stock units. (A significant component of operating expenses, particularly in R&D and G&A, totaling $10,996K and $70,825K for R&D and G&A respectively in Q3 2025, highlighting the cost of retaining talent.)

Noncontrolling Interests

The portion of equity in a subsidiary that is not attributable to the parent company. It represents the ownership interest of outside shareholders in the consolidated entity. (Represents a substantial portion of the company's equity ($443.127 million as of September 30, 2025), indicating significant ownership by others in its consolidated subsidiaries.)

Year-Over-Year Comparison

Compared to the prior year's filing (presumably for the period ending March 31, 2025, or a comparable period in 2024), Roivant Sciences has experienced a dramatic downturn in revenue, with Q3 2025 revenue falling 64.9% and H1 2025 revenue down 70%. This revenue decline is accompanied by a significant shift from retained earnings to an accumulated deficit, indicating substantial losses. While cash and cash equivalents have been depleted by over 54%, the company has increased its holdings in marketable securities, suggesting a strategic shift in liquidity management. New risks related to the company's limited operating history and ongoing substantial operating losses are prominent.

Key Financial Figures

• $0.0000000341740141 — ge on which registered Common Shares, $0.0000000341740141 per share ROIV The Nasdaq Global Sele

Filing Documents

• roiv-20250930.htm (10-Q) — 2011KB
• roiv-20250930xexx311.htm (EX-31.1) — 9KB
• roiv-20250930xexx312.htm (EX-31.2) — 9KB
• roiv-20250930xexx321.htm (EX-32.1) — 5KB
• roiv-20250930xexx322.htm (EX-32.2) — 5KB
• 0001635088-25-000016.txt ( ) — 8100KB
• roiv-20250930.xsd (EX-101.SCH) — 58KB
• roiv-20250930_cal.xml (EX-101.CAL) — 86KB
• roiv-20250930_def.xml (EX-101.DEF) — 269KB
• roiv-20250930_lab.xml (EX-101.LAB) — 669KB
• roiv-20250930_pre.xml (EX-101.PRE) — 488KB
• roiv-20250930_htm.xml (XML) — 910KB

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited) 6 Condensed Consolidated Balance Sheets as of September 30, 2025 and March 31, 2025 6 Condensed Consolidated Statements of Operations for the Three and Six Months Ended September 30, 2025 and 2024 7 Condensed Consolidated Statements of Comprehensive Loss for the Three and Six Months Ended September 30, 2025 and 2024 9 Condensed Consolidated Statements of Shareholders' Equity for the Three and Six Months Ended September 30, 2025 and 2024 10 Condensed Consolidated Statements of Cash Flows for the Six Months Ended September 30, 2025 and 2024 11 Notes to Condensed Consolidated Financial Statements 12 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 30 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 44 Item 4.

Controls and Procedures

Controls and Procedures 45

—OTHER INFORMATION

PART II—OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 46 Item 1A.

Risk Factors

Risk Factors 46 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 117 Item 3. Defaults Upon Senior Securities 117 Item 4. Mine Safety Disclosures 118 Item 5. Other Information 118 Item 6. Exhibits 119

SIGNATURES

SIGNATURES 120 Table of Contents Where You Can Find More Information Investors and others should note that we may announce material business and financial information to our investors using our investor relations website (https://investor.roivant.com), filings we make with the Securities and Exchange Commission (the "SEC"), our corporate account on the social media platform X (formerly Twitter) (@Roivant), other social media platforms, webcasts, press releases and conference calls. Similarly, Immunovant, Inc., as well as our other subsidiaries, may announce material business and financial information to its investors and others using its investor relations website (https://immunovant.com/investors), filings it makes with the SEC, social media platforms, webcasts, press releases and conference calls. We and our subsidiaries use these mediums to communicate with our and our subsidiaries' shareholders and the public about our company, our subsidiaries, our product candidates and other matters. It is possible that the information that we make available in this manner may be deemed to be material information. We therefore encourage investors and others interested in our company and our subsidiaries to review this information. The above-referenced information is not incorporated by reference into this filing and the website addresses and X account name are provided only as inactive textual references. Summary Risk Factors You should consider carefully the risks described under "Risk Factors" in Part II, Item 1A. of this Quarterly Report on Form 10-Q. Unless the context otherwise requires, references in this section to "we," "us," "our," "Roivant" and the "Company" refer to Roivant Sciences Ltd. and its consolidated subsidiaries and affiliates, as the context requires. A summary of the risks that could materially and adversely affect our business, financial condition, operating results and prospects include the following: Risks Related to Our Business and Industr

Forward-Looking Statements

Forward-Looking Statements This Quarterly Report on Form 10-Q contains statements, including matters discussed under Part I, Item 2. "Management's Discussion and Analysis of Financial Condition and Results of Operations," Part II, Item 1. "Legal Proceedings," Part II, Item 1A. "Risk Factors" and in other sections of this report, that are "forward-looking statements" within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. Our forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding the future, and statements that are not historical facts. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "would" and similar expressions 3 Table of Contents may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements contained in this Quarterly Report on Form 10-Q are based on our current expectations and beliefs concerning future developments and their potential effects on us taking into account information currently available to us. There can be no assurance that future developments affecting us will be those that we have anticipated. Should one or more of these risks or uncertainties materialize, they could cause our actual results to differ materially from the forward-looking statements. Some factors that could cause actual results to differ include, but are not limited to risk associated with: our relatively limited operating history and the inherent uncertainties and risks involved in biopharmaceutical product dev

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION

Financial Statements (Unaudited)

Item 1. Financial Statements (Unaudited). ROIVANT SCIENCES LTD. Condensed Consolidated Balance Sheets (unaudited, in thousands, except share and per share amounts) September 30, 2025 March 31, 2025 Assets Current assets: Cash and cash equivalents $ 1,237,010 $ 2,715,411 Marketable securities (includes $ 2,788,781 of available-for-sale marketable securities held at fair value as of September 30, 2025) 3,148,825 2,171,480 Other current assets 125,811 113,173 Total current assets 4,511,646 5,000,064 Property and equipment, net 25,667 12,056 Operating lease right-of-use assets 85,136 89,021 Investments measured at fair value 412,315 302,939 Other assets 27,834 32,860 Total assets $ 5,062,598 $ 5,436,940 Liabilities and Shareholders' Equity Current liabilities: Accounts payable $ 15,064 $ 23,691 Accrued expenses 108,315 114,294 Operating lease liabilities 9,002 9,842 Other current liabilities 1,476 1,584 Total current liabilities 133,857 149,411 Liability instruments measured at fair value 33,269 9,981 Operating lease liabilities, noncurrent 89,844 90,328 Other liabilities 170 22 Total liabilities 257,140 249,742 Commitments and contingencies (Note 11) Shareholders' equity: Common shares, par value $ 0.0000000341740141 per share, 7,000,000,000 shares authorized and 689,697,370 and 695,938,323 shares issued and outstanding at September 30, 2025 and March 31, 2025, respectively — — Additional paid-in capital 4,771,880 4,562,107 (Accumulated deficit) / retained earnings ( 429,107 ) 116,060 Accumulated other comprehensive income 19,558 9,438 Shareholders' equity attributable to Roivant Sciences Ltd. 4,362,331 4,687,605 Noncontrolling interests 443,127 499,593 Total shareholders' equity 4,805,458 5,187,198 Total liabilities and shareholders' equity $ 5,062,598 $ 5,436,940 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 6 Table of Contents ROIVANT SCIENCES LTD. Condensed

View Full Filing

View this 10-Q filing on SEC EDGAR